000			01500 a2200385 4500
005			20250514042838.0
264		0	_c20030122
008			200301s 0 0 eng d
022			_a0306-5251
024	7		_a10.1046/j.1365-2125.2001.01491.x _2doi
040			_aNLM _beng _cNLM
100	1		_avan de Vijver, D A M C
245	0	0	_aStart of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. _h[electronic resource]
260			_bBritish journal of clinical pharmacology _cAug 2002
300			_a168-70 p. _bdigital
500			_aPublication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAntidepressive Agents, Tricyclic _xtherapeutic use
650	0	4	_aAntiparkinson Agents _xtherapeutic use
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aLevodopa _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aParkinson Disease _xdrug therapy
650	0	4	_aSelective Serotonin Reuptake Inhibitors _xtherapeutic use
650	0	4	_aTreatment Outcome
700	1		_aRoos, R A C
700	1		_aJansen, P A F
700	1		_aPorsius, A J
700	1		_ade Boer, A
773	0		_tBritish journal of clinical pharmacology _gvol. 54 _gno. 2 _gp. 168-70
856	4	0	_uhttps://doi.org/10.1046/j.1365-2125.2001.01491.x _zAvailable from publisher's website
999			_c12088610 _d12088610